南京百鑫愉医药

Nanjing Biosnwill Pharmaceutical Co., Ltd. (Biosnwill) is a Chinese biopharmaceutical company focused on the development of improved new drugs (Class 2.2 modified new drugs) to address unmet clinical needs, particularly in neurological and cerebrovascular diseases. Co-founded by an experienced industry R&D team, the company collaborates closely with leading domestic hospitals and academic institutions, such as Beijing Tiantan Hospital. Biosnwill's flagship product, Edaravone Sublingual Tablets, was approved in China in September 2022 as the world's first sublingual formulation of edaravone for the treatment of amyotrophic lateral sclerosis (ALS). The company is also advancing clinical trials for Edaravone Sublingual Tablets in other indications, including acute ischemic stroke and cerebral small vessel disease, alongside a pipeline of preclinical candidates.